
Tawanda Gumbo MD
Mycobacterial Disease
Director of Research Programs in Global Health & Associate Professor of Medicine
Join to view full profile
UT Harry Hines BlvdStop 5323Dallas, TX 75390
Phone+1 214-648-9914
Fax+1 214-648-2741
Dr. Gumbo is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Infectious Disease, 1996 - 1999
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 1993 - 1996
University of Zimbabwe Huggins SOMClass of 1991
Certifications & Licensure
TX State Medical License 2009 - 2018
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsRigor and reproducibility of hollow-fiber infection model for antiviral pharmacokinetics/pharmacodynamics studies.Shashikant Srivastava, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy. 2026-09-03 - 1 citationsSystematic and quantitative analyses of hollow fiber model oflung disease studies and new dosing recommendations.Shashikant Srivastava, Tawanda Gumbo
Microbiology Spectrum. 2026-06-02 - Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens forlung disease.Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, Mary C Long, Brian Robbins
Antimicrobial Agents and Chemotherapy. 2026-05-06
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationTawanda Gumbo, MD, Oxford University Press
- Oxford University Press Has Registered This DOI Pre-PublicationTawanda Gumbo, Devyani Deshpande, Oxford University Press
- Oxford University Press Has Registered This DOI Pre-PublicationDevyani Deshpande, Tawanda Gumbo, Oxford University Press
Press Mentions
Praedicare Inc. Receives Grant to Evaluate Potential New Drug Regimens for TuberculosisJune 17th, 2021
New Tool for an Old Disease: Use of PET and CT Scans May Help Develop Shorter TB TreatmentFebruary 24th, 2020
New Tool for an Old Disease: Use of PET and CT Scans May Help Develop Shorter TB TreatmentFebruary 24th, 2020
Grant Support
- PK-PD Of Combination Antituberculosis Therapy For Suppression Of Drug-ResistanceNational Institute Of Allergy And Infectious Diseases2008–2011
- Efflux PUMP Inhibitors To Reduce Duration Of Antituberculosis TherapyOffice Of The Director, National Institutes Of Health2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: